Formulation, Optimization, and Ex vivo Permeation Study of Ritonavir-loaded Solid Lipid Nanoparticles.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Prathap Madeswara Guptha, Narahari N Palei, Surendran Vijayaraj, Bibhash Chandra Mohanta, Vanangamudi Murugesan
{"title":"Formulation, Optimization, and Ex vivo Permeation Study of Ritonavir-loaded Solid Lipid Nanoparticles.","authors":"Prathap Madeswara Guptha, Narahari N Palei, Surendran Vijayaraj, Bibhash Chandra Mohanta, Vanangamudi Murugesan","doi":"10.2174/0113816128329768241230071303","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ritonavir (RTV) is an antiviral drug that prevents human immunodeficiency virus (HIV). However, it has low bioavailability, which can be improved with the assistance of Solid Lipid Nanoparticles (SLNs).</p><p><strong>Objective: </strong>The present work aimed to formulate and optimize RTV-loaded SLNs using Box-Behnken design and evaluate the permeability coefficient using ex vivo permeation studies.</p><p><strong>Methods: </strong>RTV-SLNs were prepared using the ultrasonication technique. The SLN formulation was optimized based on particle size, % entrapment efficiency, and % cumulative drug release using response surface methodology resulting from Box-Behnken design. The Fourier-Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and transmission Electron Microscopy (TEM) studies were carried out for the characterization of optimized SLN formulation. Ex vivo permeation studies were also performed using chicken ileum.</p><p><strong>Results: </strong>The optimized RTV-SLNs had a particle size of 270.34 nm, polydispersity index of 0.157, and zeta potential of -25.2 mV. The % entrapment efficiency and % cumulative drug release were found to be 94.33% and 67.13%, respectively. The FT-IR study revealed that SLNs showed no significant interactions between the drug and lipid in the formulation. The % crystalline index of the RTV-loaded SLN formulation was found to be 44.31% compared to the reference value of 100% for lipids. TEM analysis showed spherical nanoparticles that were uniform in shape. The release kinetics data demonstrated the drug release behavior, followed by the Korsmeyer-Peppas model, and suggested that the release from SLNs followed the non-fiction diffusion. The permeability coefficient of optimized SLN formulation was found to be significantly (p < 0.05) more compared to free RTV suspension. The enhancement ratio results suggested that RTV-SLNs permeated significantly (p < 0.05) faster (approximately 3.5 times) as compared to free RTV suspension.</p><p><strong>Conclusion: </strong>The optimized RTV-SLNs could be a promising carrier for improving the oral bioavailability of RTV.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128329768241230071303","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ritonavir (RTV) is an antiviral drug that prevents human immunodeficiency virus (HIV). However, it has low bioavailability, which can be improved with the assistance of Solid Lipid Nanoparticles (SLNs).

Objective: The present work aimed to formulate and optimize RTV-loaded SLNs using Box-Behnken design and evaluate the permeability coefficient using ex vivo permeation studies.

Methods: RTV-SLNs were prepared using the ultrasonication technique. The SLN formulation was optimized based on particle size, % entrapment efficiency, and % cumulative drug release using response surface methodology resulting from Box-Behnken design. The Fourier-Transform Infrared spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and transmission Electron Microscopy (TEM) studies were carried out for the characterization of optimized SLN formulation. Ex vivo permeation studies were also performed using chicken ileum.

Results: The optimized RTV-SLNs had a particle size of 270.34 nm, polydispersity index of 0.157, and zeta potential of -25.2 mV. The % entrapment efficiency and % cumulative drug release were found to be 94.33% and 67.13%, respectively. The FT-IR study revealed that SLNs showed no significant interactions between the drug and lipid in the formulation. The % crystalline index of the RTV-loaded SLN formulation was found to be 44.31% compared to the reference value of 100% for lipids. TEM analysis showed spherical nanoparticles that were uniform in shape. The release kinetics data demonstrated the drug release behavior, followed by the Korsmeyer-Peppas model, and suggested that the release from SLNs followed the non-fiction diffusion. The permeability coefficient of optimized SLN formulation was found to be significantly (p < 0.05) more compared to free RTV suspension. The enhancement ratio results suggested that RTV-SLNs permeated significantly (p < 0.05) faster (approximately 3.5 times) as compared to free RTV suspension.

Conclusion: The optimized RTV-SLNs could be a promising carrier for improving the oral bioavailability of RTV.

利托那韦固体脂质纳米颗粒的制备、优化及体外渗透研究。
背景:利托那韦(Ritonavir, RTV)是一种预防人类免疫缺陷病毒(HIV)的抗病毒药物。然而,它具有较低的生物利用度,可以通过固体脂质纳米颗粒(SLNs)的辅助来改善。目的:采用Box-Behnken设计方法制备和优化rtv负载的sln,并通过体外渗透研究评价其渗透系数。方法:采用超声技术制备rtv - sln。采用Box-Behnken设计的响应面法,根据粒径、包封率和累积释药率对SLN处方进行优化。采用傅里叶变换红外光谱(FT-IR)、差示扫描量热法(DSC)和透射电镜(TEM)对优化后的SLN配方进行了表征。体外渗透研究也用鸡回肠进行。结果:优化后的RTV-SLNs粒径为270.34 nm,多分散性指数为0.157,zeta电位为-25.2 mV。包封率为94.33%,累积释药率为67.13%。FT-IR研究显示,sln在药物和制剂中的脂质之间没有显着的相互作用。rtv负载的SLN制剂的%结晶指数为44.31%,而脂类的参考值为100%。透射电镜分析表明,纳米颗粒呈球形,形状均匀。释放动力学数据显示药物释放行为符合Korsmeyer-Peppas模型,表明sln的释放遵循非虚拟扩散。与游离RTV悬浮液相比,优化后的SLN配方的渗透系数显著提高(p < 0.05)。增强比结果显示,RTV- sln的渗透速度显著加快(p < 0.05),约为游离RTV悬液的3.5倍。结论:优化后的RTV- sln为提高RTV的口服生物利用度提供了良好的载体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信